3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      DPP-4 inhibitors.

      Best Practice & Research. Clinical Endocrinology & Metabolism

      Adamantane, adverse effects, analogs & derivatives, therapeutic use, Animals, Body Weight, drug effects, Diabetes Mellitus, Type 2, drug therapy, Dipeptidyl-Peptidase IV Inhibitors, Drug Therapy, Combination, Glucagon, secretion, Glucagon-Like Peptide 1, antagonists & inhibitors, physiology, Humans, Hypoglycemia, chemically induced, Hypoglycemic Agents, Insulin, Lipid Metabolism, Metformin, Nitriles, Protease Inhibitors, Pyrazines, Pyrrolidines, Substrate Specificity, Thiazolidinediones, Triazoles

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion, thereby lowering glucose levels. Several DPP-4 inhibitors are in clinical development. Most experience so far has been with sitagliptin (Merck; approved by the FDA) and vildagliptin (Novartis; filed). These are orally active compounds with a long duration, allowing once-daily administration. Both sitagliptin and vildagliptin improve metabolic control in type-2 diabetes, both in monotherapy and in combination with metformin and thiazolidinediones. A reduction in HbA(1c) of approximately 1% is seen in studies of DPP-4 inhibition of up to 52 weeks' duration. DPP-4 inhibition is safe and well tolerated, the risk of hypoglycaemia is minimal, and DPP-4 inhibition is body-weight neutral. DPP-4 inhibition is suggested to be a first-line treatment of type-2 diabetes, particularly in its early stages in combination with metformin. However, the durability and long-term safety of DPP-4 inhibition remain to be established.

          Related collections

          Author and article information

          Journal
          18054733
          10.1016/j.beem.2007.07.005

          Comments

          Comment on this article